IP Library Patent Application 17486274
Patent Application
App. No. 17/486,274

METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/486,274
Abstract

Methods and systems are provided for producing codeinone within an engineered non-plant cell. The method comprises, within the engineered non-plant cell, producing a thebaine product. The method also comprises, within the engineered non-plant cell, contacting the thebaine product with an enzyme having thebaine 6-O-demethylase activity, thereby producing a neopinone product. Additionally, the method comprises, within the engineered non-plant cell, contacting the neopinone product with a neopinone isomerase, thereby producing a codeinone product.

Claims (36)

1 . A method of producing codeinone within an engineered non-plant cell, the method comprising:

within the engineered non-plant cell, producing a thebaine product;

within the engineered non-plant cell, contacting the thebaine product with an enzyme having thebaine 6-O-demethylase activity, thereby producing a neopinone product; and

within the engineered non-plant cell, contacting the neopinone product with a neopinone isomerase, thereby producing a codeinone product.

2 . The method of claim 1 , wherein the neopinone isomerase is an engineered neopinone isomerase.

3 . The method of claim 1 , further comprising:

within the engineered non-plant cell, contacting the codeinone product with an enzyme having morphinone reductase activity, thereby producing a hydrocodone product.

4 . The method of claim 1 , further comprising:

within the engineered non-plant cell, contacting the codeinone product with an enzyme having codeinone reductase activity, thereby producing a codeine product.

5 . The method of claim 1 , further comprising:

within the engineered non-plant cell, contacting the codeinone product with an enzyme having morphine dehydrogenase activity, thereby producing a codeine product.

6 . A method of isomerizing neopinone within an engineered non-plant cell, the method comprising:

contacting a neopinone product with a neopinone isomerase,

wherein contacting the neopinone product with the neopinone isomerase isomerizes the neopinone product to a codeinone product, and

wherein the neopinone isomerase is produced by culturing an engineered non-plant cell having at least one coding sequence, encoded within a chromosome within the engineered non-plant cell, for encoding the neopinone isomerase.

7 . The method of claim 6 , wherein the neopinone isomerase is an engineered neopinone isomerase.

8 . The method of claim 6 , further comprising:

within the engineered non-plant cell, contacting the codeinone product with an enzyme having morphinone reductase activity, thereby producing a hydrocodone product.

9 . The method of claim 6 , further comprising:

within the engineered non-plant cell, contacting the codeinone product with an enzyme having codeinone reductase activity, thereby producing a codeine product.

10 . The method of claim 6 , further comprising:

within the engineered non-plant cell, contacting the codeinone product with an enzyme having morphine dehydrogenase activity, thereby producing a codeine product.

11 . The method of claim 1 , wherein at least one of products selected from the group consisting of the thebaine product and the neopinone product is produced within the engineered non-plant cell from a simple starting material.

12 . The method of claim 11 , wherein the simple starting material comprises a sugar.

13 . The method of claim 1 , further comprising:

contacting the codeinone product, or a derivative thereof, with one or more enzymes selected from the group consisting of: morphinone reductase, morphine dehydrogenase, codeinone reductase, N-demethylase, N-methyltransferase, and neopinone isomerase,

thereby producing at least one product selected from the group consisting of: a neopinone, 14-Hydroxycodeinone, oxycodone, oxymorphone, noroxymorphone, noroxymorphol, buprenorphine, naloxone, naltrexone, and nalbuphine.

14 . The method of claim 3 , further comprising:

contacting the hydrocodone product, or a derivative thereof, with one or more enzymes selected from the group consisting of: a morphine dehydrogenase, codeinone reductase, and codeine O-demethylase,

thereby producing at least one product selected from the group consisting of: hydromorphone and dihydrocodeine.

15 . The method of claim 4 , further comprising:

contacting the codeine product, or a derivative thereof, with one or more enzymes selected from the group consisting of: morphine dehydrogenase, codeinone reductase, codeine O-demethylase, and neopinone isomerase,

thereby producing at least one product selected from the group consisting of: a codeinone, neopinone, neopine, neomorphine, morphine, neomorphinone, and morphinone.

16 . The method of claim 1 , wherein the engineered non-plant cell is an engineered fungal cell or an engineered bacteria cell.

17 . The method of claim 16 , wherein the engineered non-plant cell is an engineered fungal cell.

18 . The method of claim 16 , wherein the engineered non-plant cell is an engineered bacteria cell.

Assignments (1)
SECURITY INTEREST Recorded Aug 29, 2025
From: ANTHEIA, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 072750/0812 →